A lymph node biopsy report has three main sections: a gross (visible) description of the tissue, a microscopic description of what the cells look like under magnification, and a final diagnosis that pulls everything together. The diagnosis section is where you’ll find the answer to the big question: whether the lymph node shows signs of cancer, infection, or a normal immune response. Understanding what each section means, and what key terms to look for, can help you make sense of the report before or after your follow-up appointment.
The Three Sections of a Pathology Report
Every lymph node biopsy report follows a standard structure. The first section, called the gross description, covers what the pathologist could see with the naked eye. This includes the size, color, weight, and shape of the tissue sample, along with which body site it came from and how many lymph nodes were removed. A lymph node measuring more than 1 cm in its short axis is generally considered abnormal, though this threshold varies by location. Abdominal lymph nodes, for instance, have upper limits ranging from 6 to 10 mm depending on their exact position.
The second section is the microscopic description. Here the pathologist describes what the cells look like after staining and viewing under a microscope. The standard staining method colors genetic material in the cell nucleus a deep blue-purple, while the surrounding cell structures appear orange-pink-red. This lets the pathologist evaluate the pattern, shape, and arrangement of cells, how abnormal they look (the tumor grade, if cancer is present), and whether abnormal cells appear at the edges of the removed tissue.
The third and most important section is the final diagnosis. This is the pathologist’s summary combining everything they observed with your clinical information. If cancer is found, this section identifies the type, grade, and stage. If no cancer is present, it typically describes what is causing the lymph node changes.
What “Reactive” Means on Your Report
One of the most common findings on a lymph node biopsy is “reactive lymphadenopathy” or “reactive hyperplasia.” This is good news. It means your lymph node is enlarged because your immune system is actively responding to something, most often a viral infection. Bacterial infections, particularly from streptococcal or staphylococcal bacteria, account for 40% to 80% of cases where only one side is affected.
A reactive lymph node preserves its normal internal architecture. The pathologist can still see the organized zones where different immune cells live and work. The cells are polyclonal, meaning they represent a diverse, healthy mix of immune cells rather than one abnormal population multiplying out of control. Most reactive lymphadenopathy is self-limiting and resolves on its own.
Terms That Suggest Cancer
Certain phrases in the microscopic description or diagnosis are red flags for malignancy. “Effacement of architecture” means the lymph node’s normal internal structure has been replaced or destroyed, often by abnormal cells. “Atypical cells” or “atypical lymphoid proliferation” indicates cells that don’t look normal under the microscope. “Monoclonal” or “monoclonality” means the cells appear to come from a single clone, which is a hallmark of lymphoma rather than a normal immune response.
If cancer from another organ has spread to the lymph node, you may see terms like “metastatic carcinoma,” “consistent with metastatic disease,” or a specific origin such as “metastatic adenocarcinoma consistent with breast primary.” The report may also note “extracapsular extension,” meaning cancer cells have grown beyond the outer wall of the lymph node into surrounding tissue, which affects staging and treatment planning.
Staging terminology in the report often follows the TNM system. The “N” value refers to lymph node involvement: N0 means no cancer in nearby lymph nodes, while N1, N2, or N3 indicates increasing levels of spread. The “M” value addresses distant metastasis: M0 means no distant spread, M1 means cancer has reached other parts of the body. Sometimes the report will note “isolated tumor cells” or “micrometastasis,” which describe very small deposits of cancer cells in a lymph node, each carrying different implications for staging.
Special Stains and Immunohistochemistry
If the standard staining doesn’t give a clear answer, the pathologist orders additional tests called immunohistochemistry (IHC). These use antibodies to detect specific proteins on the surface of cells, helping to identify exactly what type of cells are present. Your report may list results for markers like CD20, CD3, CD30, or Ki-67. Here’s what the most common ones mean in practical terms.
CD20 is a protein found on the surface of B cells, one of the two main types of immune cells. If abnormal cells are CD20-positive, the pathologist is likely looking at a B-cell lymphoma. CD3 marks T cells, the other major type, and its presence on abnormal cells points toward T-cell lymphoma. CD30, a different surface protein, shows up strongly in classic Hodgkin lymphoma and in a specific type of T-cell lymphoma called anaplastic large cell lymphoma. Ki-67 is a measure of how fast cells are dividing. A Ki-67 labeling index greater than 80% suggests a highly aggressive lymphoma.
These markers often appear in combinations. For example, classic Hodgkin lymphoma cells typically test positive for CD30 but negative for CD20. A less common form called nodular lymphocyte-predominant Hodgkin lymphoma shows the opposite pattern: CD20-positive, CD30-negative. Diffuse large B-cell lymphoma, the most common aggressive lymphoma, usually shows large atypical cells that are CD20-positive and CD3-negative. If you’ve previously received certain treatments like rituximab, a CD20-targeted therapy, the results can shift, so your treatment history matters for interpretation.
Flow Cytometry Results
Some biopsy reports include flow cytometry, a test that rapidly analyzes thousands of individual cells to determine what surface proteins they carry. The key distinction flow cytometry makes is between polyclonal and monoclonal cell populations.
Polyclonal means the B cells in your lymph node produce a healthy variety of antibody types. This is the normal pattern seen in reactive conditions, infections, autoimmune diseases, and even in response to stress or smoking. Monoclonal means an abnormally large population of B cells all express the same antibody type, suggesting they descended from a single cell that began multiplying uncontrollably. Monoclonality is a strong indicator of lymphoma or a related condition.
Flow cytometry can also identify specific disease patterns. For example, chronic lymphocytic leukemia has a characteristic signature where cells express a particular combination of surface proteins (CD5, CD19, and CD23 together, with weak CD20). If flow cytometry detects a monoclonal population that doesn’t fit the typical pattern for any recognized condition, the report will usually recommend additional testing such as imaging or bone marrow biopsy.
How Long Results Take
Standard biopsy results typically come back within two to three days. If the pathologist needs immunohistochemistry or other special stains, add one to two additional days. Flow cytometry results can take a similar timeframe. In complex cases where the pathologist requests outside consultation or molecular testing, the complete report may take one to two weeks. If your results are taking longer than expected, it often means additional testing was needed for accuracy rather than indicating a worse outcome.
Questions Worth Asking at Your Follow-Up
Having your report in hand before your appointment lets you prepare targeted questions. If cancer is found, the most useful questions to bring are:
- What type and stage is it? The specific lymphoma subtype or cancer origin determines the treatment approach.
- Has it spread beyond the lymph nodes? This determines whether additional imaging or biopsies are needed.
- What additional tests are still pending? Molecular or genetic studies can take weeks and may change the diagnosis or treatment plan.
- What does the grade mean for my prognosis? Low-grade and high-grade lymphomas behave very differently, and some low-grade types are monitored rather than treated immediately.
If the report says “reactive” or “benign,” it’s still worth asking whether follow-up imaging or repeat biopsy is recommended, particularly if the lymph node remains enlarged. In rare cases, lymphoma can coexist with reactive changes, and a single biopsy may not capture the full picture.